Literature DB >> 2545908

Identification and expression of a human cytomegalovirus early glycoprotein.

C P Chang1, D H Vesole, J Nelson, M B Oldstone, M F Stinski.   

Abstract

A human cytomegalovirus early gene which possesses three temporally regulated promoters is located in the large unique component of the viral genome between 0.054 and 0.064 map units (C.-P. Chang, C.L. Malone, and M.F. Stinski, J. Virol. 63:281-290, 1989). This gene contains a major open reading frame (ORF) located 233 bases downstream of the cap site of an early unspliced RNA. The major ORF predicts a polypeptide of 17 kilodaltons (kDa) which contains a glycoproteinlike signal and anchor domains as well as potential N-glycosylation sites. Antisera were prepared against synthetic peptides derived from amino acid sequences within the major ORF. The antisera detected a viral glycoprotein of 48 kDa in infected cells and recognized the in vitro-translated 17-kDa protein early-gene product. The viral glycoprotein, designated gp48, was modified by N-linked glycans and possibly O-linked glycans. The synthesis of gp48 occurred in the absence of viral DNA replication but accumulated to the highest levels at late times after infection. Since gp48 was found in the virion, it is considered an early structural glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545908      PMCID: PMC250906          DOI: 10.1128/JVI.63.8.3330-3337.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Regulation of cytomegalovirus late gene expression: gamma genes are controlled by posttranscriptional events.

Authors:  A P Geballe; F S Leach; E S Mocarski
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

4.  Temporal patterns of human cytomegalovirus transcription: mapping the viral RNAs synthesized at immediate early, early, and late times after infection.

Authors:  M W Wathen; M F Stinski
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

5.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus.

Authors:  L Rasmussen; J Mullenax; R Nelson; T C Merigan
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

7.  Analysis of adenovirus transforming proteins from early regions 1A and 1B with antisera to inducible fusion antigens produced in Escherichia coli.

Authors:  K R Spindler; D S Rosser; A J Berk
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

8.  Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.

Authors:  L E Rasmussen; R M Nelson; D C Kelsall; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Influences of mRNA secondary structure on initiation by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

10.  Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies.

Authors:  L Pereira; M Hoffman; M Tatsuno; D Dondero
Journal:  Virology       Date:  1984-11       Impact factor: 3.616

View more
  35 in total

1.  Abundant early expression of gpUL4 from a human cytomegalovirus mutant lacking a repressive upstream open reading frame.

Authors:  J P Alderete; S J Child; A P Geballe
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication.

Authors:  Veronica Sanchez; Charles L Clark; Judy Y Yen; Roopashree Dwarakanath; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Role of regulatory elements and the MAPK/ERK or p38 MAPK pathways for activation of human cytomegalovirus gene expression.

Authors:  Jiping Chen; Mark F Stinski
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Activation of transcription of the human cytomegalovirus early UL4 promoter by the Ets transcription factor binding element.

Authors:  J Chen; M F Stinski
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Expression of a human cytomegalovirus glycoprotein multigene family.

Authors:  D R Gretch; J F Bale; R C Gehrz; M F Stinski
Journal:  Virus Genes       Date:  1991-07       Impact factor: 2.332

6.  Translational control of human cytomegalovirus gp48 expression.

Authors:  M R Schleiss; C R Degnin; A P Geballe
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  Spliced transcripts of human cytomegalovirus.

Authors:  W D Rawlinson; B G Barrell
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Characterization of a human cytomegalovirus 1.6-kilobase late mRNA and identification of its putative protein product.

Authors:  R S Lahijani; E W Otteson; J D Adlish; S C St Jeor
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Fine mapping of transcripts expressed from the US6 gene family of human cytomegalovirus strain AD169.

Authors:  T R Jones; V P Muzithras
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

10.  Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion.

Authors:  Matthew Lopper; Teresa Compton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.